Scientific Collaboration in Clinical Pharmacology
Conditions
Keywords
Clinical pharmacology, studies on humans, recently published
Brief summary
It is unknown in which countries the clinical pharmacology studies published in leading specialized journals were conducted. The hypothesis is that studies in this specialty tend to be conducted and published by authors from a single country. This analysis aims to describe the number of collaborators and the countries in which they worked, using the Nature Index concept of "share."
Detailed description
Original articles (full reports, short communications, research letters) on human participants, data, or material published in the seven top (as per Journal Citations Report 2024 Impact Factor) clinical pharmacology hybrid journals linked to clinical pharmacology professional societies will be included. Articles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes first. The country of the main authors (first author/last author) and the countries where all the contributors listed in the article's byline worked will be recorded. Collaboration index and degree of collaboration will be calculated. The contribution of all countries will be calculated using the Nature index's "share" concept.Depending on whether a high percentage of articles are written by authors from the same country as a given journal (and scientific society), the need to adjust the results to reflect a situation closer to reality in terms of the importance of different countries in the publication of the articles evaluated will be assessed. As a proxy, the relevance of each country in contributing to clinical pharmacology research will be calculated by multiplying the "share" score by the JCR impact factor of each journal and adding the scores obtained from the seven journals. In addition, In addition, following slightly modified terminology used by ClinicalTrials.gov, the type of sector (industry, government institutions, and 'Others') will also be recorded to help characterize the studies evaluated. However, the 'Others' category will be classified into hospitals, universities, and research centers. Funding will be recorded as public, private, and public-private.
Interventions
Articles on human participants, data, or material published in top (as per JCR IF) clinical pharmacology journals linked to professional societies
Sponsors
Study design
Eligibility
Inclusion criteria
* Articles on human participants, data or material. Original articles, short reports, research letters.
Exclusion criteria
* In vitro studies, animal studies. Editorials, letters, commentaries, perspectives.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| countries where authors conducted their study | Articles of interest to be included from the June 2025 issue backwards until reaching 100 articles or until the January 2024 issue, whichever comes first | The country of the principal authors and of all collaborators will be registered following Nature Index 'share' concept |
Countries
Spain
Contacts
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz